FAST NEWS: Junshi Biosciences Oral Covid Drug Wraps Up Trials, to Seek Sales Approval
The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) announced late Monday that VV116, an oral drug developed by its JunTop Biosciences unit for the early treatment of Covid-19, has reached the main endpoint…
RELATED ARTICLES
-
As Covid drug cash dwindles, Vigonvita targets new remedies
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
